Navigation Links
BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
Date:11/7/2007

BURLINGAME, Calif., Nov. 7 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that Michael C. Venuti, Ph.D., has joined the Company as its Chief Executive Officer and member of the Board of Directors. Dr. Venuti succeeds Peter D. Staple, who will continue his involvement with the Company as an investor and Board member. Dr. Venuti previously served as Chief Executive Officer of Discovery Partners International, a small molecule-based drug discovery services company.

Fred Craves, Managing Director and Founder of Bay City Capital, which is a major investor in BioSeek, commented, "We welcome Michael to BioSeek, as we believe his leadership and specific experience in drug discovery will be important as BioSeek strives to expand its proprietary drug discovery activities. This new direction was highlighted by our recent research collaboration with Amylin Pharmaceuticals to discover novel peptide therapeutics. We thank Peter Staple for his important contributions to BioSeek, including taking the Company to a new level through validating corporate partnerships, including our relationship with Amylin."

"It's gratifying to have an individual with Michael's background and talent join us as the Company advances into an exciting new phase of development," added Peter Staple.

"I look forward to leading BioSeek in its new drug discovery-focused direction and anticipate these new initiatives will lead us to both additional partnerships and revenue-generating contracts in the future," commented Dr. Venuti. "The launching of our proprietary development programs utilizing our BioMAP(R) human biology screening systems will also provide us with additional internal value drivers."

Since the Discovery Partners merger with Infinity Pharmaceuticals in September 2006, Dr. Venuti has served as a consultant to TPG Growth Biotech Ventures, as well as to a number of biotech companies. Before becoming CEO of Discovery Partners, Dr. Venuti served as Chief Scientific Officer, and had been a member of its board of directors before becoming CSO. Prior to joining Discovery Partners, he served as General Manager of Celera Genomics Group's South San Francisco site after its acquisition of Axys Pharmaceuticals, Inc. He served as Senior Vice President, Research and Preclinical Development, of Axys Pharmaceuticals prior to its acquisition by Celera. In this capacity, he was responsible for all small molecule target identification, medicinal chemistry, drug discovery and preclinical development activities. Prior to joining Axys, Dr.Venuti was Director of Bioorganic Chemistry at Genentech, Inc., and had begun his research career in medicinal chemistry at Syntex.

Dr. Venuti holds an A.B. from Dartmouth College, a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, and completed postdoctoral training in the Institute of Organic Chemistry at Syntex Research. He is on the board of directors of Infinity Pharmaceuticals and serves as Executive Scientific Advisor to BIO Ventures for Global Health, a non-profit advocacy group focused on drug discovery and development for neglected diseases. Dr. Venuti holds an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to http://www.bioseekinc.com

BioSeek Contacts:

BioSeek, Inc.

Michael C. Venuti, Ph.D.

Chief Executive Officer

Tel: 650-552-0754

E-mail: mvenuti@bioseekinc.com

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 508.647.0209

E-mail: jgreenleaf@macbiocom.com


'/>"/>
SOURCE BioSeek, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
Breaking Medicine Technology: